Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,773 across all filing types
Latest filing 2024-05-03 Declaration of Voting R…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed sections regarding the 'Notification of Major Holdings' as per German Securities Trading Act (WpHG) requirements. It details the acquisition/disposal of shares and instruments, specifying the percentage of voting rights held by a major shareholder (T. Rowe Price International Funds, Inc.). This directly corresponds to the definition of a notification regarding changes in significant share ownership levels, which maps to the Major Shareholding Notification code (MRQ). Although the header mentions 'Voting Rights Announcements', the content is a specific regulatory filing about shareholding thresholds, making MRQ the most precise fit over DVA (which is for voting results) or RNS (the general fallback).
2024-05-03 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership ('Notification of Major Holdings') by T. Rowe Price Group, Inc. and its subsidiaries, referencing specific German securities law articles (WpHG Sections 33, 34, 38, 40). This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers changes in significant share ownership levels crossing thresholds.
2024-05-03 English
Update of the Declaration of Conformity with the German Corporate Governance Code for the Year 2023 (May 2024)
Governance Information Classification · 1% confidence The document is titled "Update of the Declaration of Conformity with the German Corporate Governance Code." It explicitly discusses compliance with the German Corporate Governance Code (Code), referencing specific recommendations (G.11, G.8) related to performance criteria and variable remuneration for the Management Board. This content directly relates to the company's internal rules, board structure, and governance practices, making it a Governance Information document. It is not an AGM presentation, a full financial report (10-K or IR), an earnings release (ER), or a remuneration report (DEF 14A), although it touches upon remuneration criteria. The core subject is the declaration of conformity regarding governance standards. Given the specific focus on governance code compliance, the most appropriate code is CGR (Governance Information). The document length is short (1763 chars), but it is the substance of the declaration itself, not an announcement *about* the declaration being published, thus RPA/RNS is less appropriate than CGR.
2024-05-01 English
Aktualisierung der Entsprechenserklärung zum Deutschen Corporate Governance Kodex für das Jahr 2023 (Mai 2024)
Governance Information Classification · 1% confidence The document is titled "Aktualisierung der Entsprechenserklärung zum Deutschen Corporate Governance Kodex" (Update to the Declaration of Conformity with the German Corporate Governance Code). It explicitly discusses the Board's (Vorstand) and Supervisory Board's (Aufsichtsrat) adherence to specific recommendations (G.8, G.11) of the German Corporate Governance Code and details adjustments made to performance criteria for variable executive compensation (Bonus). This content directly relates to the company's internal rules, board structure, and governance practices, specifically concerning executive remuneration structure as mandated by governance codes. This aligns best with the Governance Information (CGR) category, which covers internal rules and board structure. While it touches upon remuneration, the primary focus is the compliance statement regarding the governance code itself, rather than a full remuneration report (DEF 14A). Given the focus on the Corporate Governance Code compliance statement, CGR is the most appropriate fit.
2024-05-01 German
Bayer and Evotec collaborate to advance precision cardiology
Regulatory Filings Classification · 1% confidence The document is a news release dated April 30, 2024, announcing a strategic collaboration update between Bayer and Evotec regarding precision cardiology. It uses the EQS-News format, which typically disseminates timely corporate information. The content is an announcement about a business development (collaboration update) rather than a full financial report (like 10-K or IR), a formal shareholder vote result (DVA), or a management compensation disclosure (DEF 14A). Since it is a specific corporate announcement about a strategic partnership and R&D focus, it does not fit neatly into the primary financial reporting categories. It is not a standard Earnings Release (ER) or a formal regulatory filing like a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Given the nature of announcing a strategic business development, it is best classified as a general Regulatory Filing (RNS) as it is a broad category for corporate news that doesn't fit elsewhere, although 'M&A Activity' (TAR) is related to business deals, this is a collaboration, not a merger or takeover. RNS serves as the most appropriate general corporate announcement category here.
2024-04-30 English
Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth
Earnings Release Classification · 1% confidence The document explicitly states it presents 'fiscal year 2023 results' and includes detailed financial tables (Key figures of consolidated income statement) covering the period ended 31 December 2023. It also mentions 'Group revenues up 4% to € 781.4 m' and 'Adjusted Group EBITDA at € 66.4 m'. This content is characteristic of a full annual financial report. Although it is presented as a news release format (EQS-News), the substance is the comprehensive annual financial performance review, which aligns best with the Annual Report (10-K) definition, even if it is a summary/release of that information. Since the text is extensive (over 21,000 characters) and contains detailed financial figures, it is classified as the report itself rather than just a publication announcement (RPA). FY 2023
2024-04-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.